Credit Suisse's $5.00 Embarassing Target Mistake Has a Disclosure
Risk: Our $5 target price is based on Belviq cash flows alone. Risks to our target price include Belviq exceeding expectations in the US or
international markets or the overall obesity market exceeding expectations in the US or international markets.
Depends of which clients you are referring to. CS and their top clients are buying ARNA hands over fist and they will be long before the big run up. As for the rest of their clients they have a safe out by saying the launch went much better then they expected. Numbers are already out and show Belviq launch is doing much better but they are silent. That might be because they have not gotten their fill yet.